title: Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
abstract: OBJECTIVE
  To evaluate long-term survival and prognostic factors for all epithelial ovarian cancer (EOC) patients after adjuvant treatment with paclitaxel and carboplatin.
  
  
  METHODS
  Prospectively collected data from a population-based cohort.
  
  
  METHODS
  Western Sweden Health Care Region.
  
  
  METHODS
  All women diagnosed with EOC between 1998 and 2005.
  
  
  METHODS
  Data related to age, stage, surgery, histopathology, grade, ploidy status, CA-125, follow-up, recurrence and death of EOC patients (n=976) were prospectively collected in a quality register. No patient was lost to follow-up and the median follow-up was 68 months (range: 27-110).
  
  
  METHODS
  Relative survival at 5 and 8 years for all and for those treated with chemotherapy; median progression-free survival (PFS) for stage IIB-IV patients treated with paclitaxel and carboplatin.
  
  
  RESULTS
  Relative 5- and 8-year survival rates in the subgroup of patients treated with chemotherapy after surgery (n=853) were 50.4% (95% CI: 46.4-54.3) and 40.5% (95% CI: 35.4-45.6), respectively. The median relative survival time of the entire group of patients was 60 months (95% CI: 52-73). The median PFS for the patients in stage IIB-IV treated with paclitaxel and carboplatin was 18 months (95% CI: 17-20). Well-established prognostic factors of age, stage, residual tumor and post-operative CA-125 were of prognostic significance.
  
  
  CONCLUSIONS
  Post-surgical adjuvant chemotherapy of paclitaxel and carboplatin for advanced stages of EOC does not seem to increase the relative 5-year survival rate or the median PFS compared to results of earlier studies of a similar patient cohort from the same geographical area.
authors.affiliation: Department of Oncology, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden. makeson@tele2.se
authors.forename: Margaretha
authors.initials: M
authors.lastname: Akeson
authors.forename: Britt-Marie
authors.initials: BM
authors.lastname: Zetterqvist
authors.forename: Kalle
authors.initials: K
authors.lastname: Dahllöf
authors.forename: Mats
authors.initials: M
authors.lastname: Brännström
authors.forename: György
authors.initials: G
authors.lastname: Horvath
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D015996:Survival Rate; D013548:Sweden
chemical_list: D016190:Carboplatin; D017239:Paclitaxel